Earnings ·
Reports Q3 net loss of $4.8M and holds $37.8M in cash with runway into Q1 2028
APREAprea Therapeutics, Inc.
Aprea Therapeutics reported a third-quarter net loss of $4.8 million, or $0.09 per share, on approximately 53.7 million weighted-average shares. Operating expenses rose to $5.2 million from $3.1 million in the prior-year period, driven by a $2.1 million increase in research and development costs for its APR-1051 clinical trial. The company ended the quarter with $37.8 million in cash and cash equivalents, projecting a runway into the first quarter of 2028. Aprea also announced that enrollment in its ACESOT-1051 Phase 1 trial has expanded to nine sites, with interim data scheduled for presentation at the EORTC-NCI-AACR Symposium in November. The company is a clinical-stage precision medicine oncology firm developing targeted therapies for biomarker-defined cancers.